海特生物(300683) - 2024 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2024 was ¥131,887,548.36, a decrease of 4.87% compared to ¥138,635,351.99 in the same period last year[5] - The net loss attributable to shareholders was ¥16,545,525.38, representing a significant increase of 1,024.00% from a loss of ¥1,472,018.93 in the previous year[5] - The basic and diluted earnings per share were both -¥0.13, reflecting a 550.00% decline from -¥0.02 in the previous year[5] - The net profit for Q1 2024 was -17,491,671.96 CNY, compared to -1,715,296.26 CNY in Q1 2023, representing a significant increase in losses[25] - Operating profit for Q1 2024 was -27,890,510.14 CNY, compared to -6,550,452.17 CNY in the same period last year, indicating a worsening operational performance[25] - The total comprehensive income for Q1 2024 was -17,491,671.96 CNY, compared to -1,715,296.26 CNY in the same quarter last year[25] - The company incurred income tax expenses of -10,954,342.19 CNY in Q1 2024, compared to -5,099,856.83 CNY in Q1 2023[25] Cash Flow and Assets - The net cash flow from operating activities improved to ¥9,144,316.35, a 145.66% increase from a negative cash flow of ¥20,025,031.14 in the same period last year[5] - The company's cash and cash equivalents decreased to RMB 463,292,993.72 from RMB 510,216,050.96 at the beginning of the period, a decline of about 9.2%[21] - Total cash and cash equivalents at the end of Q1 2024 were 463,241,985.11 CNY, down from 665,809,620.43 CNY at the end of Q1 2023[28] - Cash flow from operating activities generated a net inflow of 9,144,316.35 CNY, a recovery from a net outflow of -20,025,031.14 CNY in Q1 2023[27] - Cash flow from investing activities resulted in a net outflow of -51,269,298.36 CNY, an improvement from -349,381,558.66 CNY in the previous year[27] - The total assets at the end of the reporting period were ¥2,965,339,512.51, a slight decrease of 0.20% from ¥2,971,251,156.62 at the end of the previous year[5] Expenses and Liabilities - The total operating costs increased to RMB 185,592,842.22 in Q1 2024, compared to RMB 154,418,438.44 in Q1 2023, marking an increase of about 20.2%[24] - Research and development expenses for Q1 2024 were RMB 27,937,527.55, up from RMB 24,195,180.16 in the previous year, indicating a growth of approximately 11.4%[24] - The total liabilities as of March 31, 2024, were RMB 487,241,012.05, compared to RMB 475,730,321.80 at the start of the period, reflecting an increase of approximately 2.7%[22] - The company's equity attributable to shareholders decreased to RMB 2,461,679,083.06 from RMB 2,478,155,270.84, a decline of about 0.7%[23] - The company reported a net asset impairment loss of RMB 17,702,519.53 in Q1 2024, compared to RMB 3,760,991.99 in the previous year, indicating a significant increase in impairment losses[24] Shareholding Structure - The total number of common shareholders at the end of the reporting period is 11,511[11] - Wuhan Sanjiangyuan Investment Development Co., Ltd. holds 19.26% of shares, totaling 25,209,424 shares[12] - Wuhan Berui Le Enterprise Management Co., Ltd. holds 11.30% of shares, totaling 14,790,576 shares[12] - Chen Ya, an overseas individual, holds 8.44% of shares, totaling 11,050,000 shares, with 8,287,500 shares pledged[12] - The shareholding structure indicates that Chen Ya is the actual controller of the company[18] - On January 17, 2024, a share transfer agreement was signed, transferring 11.30% of shares from Sanjiangyuan to Berui Le[17] - After the transfer, Sanjiangyuan retains 19.26% of shares, remaining the controlling shareholder[17] - The registered capital of Sanjiangyuan increased from RMB 20.42 million to RMB 39.87 million due to a capital increase by Chen Ya[18] - The company has undergone a restructuring of its controlling shareholder and actual controller[18] Government Support and Investments - The company received government subsidies amounting to ¥1,497,144.69, which positively impacted its financial performance[6] - The cash received from other operating activities rose significantly by 492.65% to ¥55,936,853.54, mainly due to increased government subsidies[9] - Investment income surged by 10,050.76% to ¥239,113.29, attributed to higher returns from financial products[8] - The company acquired 25.9950% equity in Beijing Shadong Biotechnology Co., increasing its total ownership to 72.5420% after an investment of RMB 51,083,580[19] Market Activity - The company did not report any new product launches or significant market expansion strategies during the quarter[29] - The company reported a decrease in sales revenue from 149,640,393.03 CNY in Q1 2023 to 133,872,412.81 CNY in Q1 2024[27]